AlloVir, Inc. (NASDAQ:ALVR) insider Beek Jeroen B. Van sold 15,201 shares of the firm’s stock in a transaction dated Tuesday, May 18th. The shares were sold at an average price of $22.80, for a total transaction of $346,582.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of ALVR traded down $1.01 during mid-day trading on Monday, hitting $22.98. The company had a trading volume of 315,977 shares, compared to its average volume of 292,994. The business’s 50-day simple moving average is $19.57 and its 200-day simple moving average is $21.92. AlloVir, Inc. has a 1-year low of $16.66 and a 1-year high of $48.96. The stock has a market cap of $1.50 billion, a PE ratio of -8.87 and a beta of 3.35.
AlloVir (NASDAQ:ALVR) last released its earnings results on Thursday, August 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.14). Research analysts forecast that AlloVir, Inc. will post -1.99 earnings per share for the current year.
ALVR has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of AlloVir from a “hold” rating to a “sell” rating in a report on Wednesday, August 11th. SVB Leerink initiated coverage on shares of AlloVir in a report on Sunday, August 22nd. They set a “buy” rating for the company. Finally, Morgan Stanley lowered their price target on shares of AlloVir from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Wednesday, August 18th.
AlloVir Company Profile
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Featured Article: Dividend Yield
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.